Pfizer Inc. has announced that it has received all the necessary regulatory approvals to finalize its acquisition of Seagen Inc., and expects to complete the deal on Thursday. To address concerns raised by the Federal Trade Commission, Pfizer has agreed to donate the rights of royalties from sales of Bavencio in the United States to the American Association for Cancer Research to support its mission of curing cancer through research and funding. Pfizer is also planning changes to its commercial organization to better integrate Seagen and improve focus and speed of execution. The company will create an end-to-end business organization called the Pfizer Oncology Division, which will combine certain commercial and R&D operations from both companies. The new structure will be implemented on Jan. 1. The move to acquire Seagen, for $43 billion, was aimed at strengthening Pfizer’s oncology business. Pfizer is planning to hold an investor day on Wednesday, during which it will offer guidance for 2024. Pfizer’s stock has declined by 44% year-to-date, while the S&P has gained 20%.